|
|
|
|
|
 |
Home |
 | |
 |
Calendar |
 | |
 |
Video |
 | |
|
 |
FAQs |
 | |
 | Upcoming Special Events |  | |
|
|
|
Search
|
Search Term
|
Filter By
|
|
|
|
|
Page
of
6
|
| |
|
|
Targeted Temperature Management
STEVEN TABACK, M.D
Department of Medicine, PSJMC.
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following:
Dr. Taback states he has no disclosures.
Objectives
At the end of the presentation, attendees will be able to:
- define TTM, its goals and rationale for use in the post-cardiac arrest patient.
- determine eligibility and exclusion criteria for TTM.
- describe and manage the effects of mild hypothermia on various body systems
- delineate the medical implications as the patient progresses through the phases of TTM therapy: induction, maintenance, re-warming and normotherima.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Advanced Clinical Integration and Accountable Care
JOHN MARREN, ESQ.
THOMAS BABBO, ESQ.
HOGAN MARRENT, LTD., CHICAG
FACULTY DISCLOURE: According to the CMA guidelines on faculty discloure of commerical support, we are required to announce the following: Mr. Marren and Mr. Babbo state they have no disclosures.
Myron Berdischewsky, M.D., planner of the clinical integration sessions, states he has no disclosures.
Objectives
At the end of the presentation, attendees will be able to: - discuss the implications of healthcare reform on the care delivery system.
-
describe current successful models of collaboration between private practice physicians and hospitals based on clinical integration across the care continuum
- articulate the legal requirements of the clinical integratin model, and how it relates to clinical quality,
- discuss what Providence California Region is doing to support physicians in continuing to deliver high quality care in the practice model of their choice.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Prevention and Treatment of Vitamin D Deficiency: Endocrinology Perspective
YAROSLAV GOFNUNG, M.D.
DEPARTMENT OF MEDICINE, PSJMC
MODERATOR: Paola Tempesti, M.D.; Department of Medicine, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Gofnung states he has no disclosures. Dr. Tempesti states she has stock in Bristol Myers Squibb.
OBJECTIVES
At the end of the presentation, attendees will be able to: - identify who is at risk for Vitamin D deficiency and recognize the signs and symptoms.
- conduct an appropriate work-up for Vitamin D status and interpret results.
- incorporate into practice the latest recommendations for prevention and treatment of Vitamin D deficiency.
- identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of Vitamin D deficiency.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Envenomations: Snakes, Spiders and other Critters
CYRUS RANGAN, M.D.
DIRECTOR, TOXICOLOGY AND ENVIRONMENTAL ASSESSMENT BUREAU
LOS ANGELES DEPARTMENT OF PUBLIC HEALTH
MODERATOR: Sheldon Kishineff, MD, Pediatric Department, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Rangan states he has no disclosures. Dr. Kishineff states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to:
|
|
Play Video
|
|
|
|
American Recovery and Reinvestment Act
DOUGLAS JONES
DIR., INFORMATION SYSTEMS, PROVIDENCE HEALTH &SERVICES, CA REGION
MODERATOR: Raffi Mesrobian, MD; Vice-Chief of Staff, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Mr. Jones states he has no disclosures. Dr. Mesrobian states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - cite the provisions of the ARRA related to HIT and EMR and determine the potential impact on hospitals and physicians in California.
- discuss how physicians can best prepare for adoption of HIT and receive federal subsidy for implementation of “meaningful use” of EMR.
- determine how PH&S California Region is assisting in the HIT alignment of physician groups and hospitals.
- identifycultural/linguistic factors such as computer literacy that impact the long-term outcomes of HIT adoption.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Common Community Orthopedic Conditions 2010
JEFFREY KORCHEK, MD
ORTHOPEDIC SECTION, PSJMC
MODERATOR: Stephan Yacoubian, MD; Chairman, Orthopedic Section, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Korchek states he has no disclosures. Dr. Yacoubian states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - recognize the signs and symptoms of common orthopedic injuries, including fractures, shoulder dislocation, arthritis of the hip, shoulder and knee, ACL tears, etc.
- conduct an appropriate work-up and make the differential diagnosis.
- incorporate current evidence-based strategies for successful management of common orthopedic injuries and/or refer to a specialist.
- identify cultural/linguistic factors or cultural disparities that impact the long-term outcomes of patients with common orthopedic injuries.
Satisfies DHS radiology requirement. This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM. This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Hand Surgical Update for the Primary Care Provider: Avoiding the Pitfalls
RAYMOND RAVEN, MD
GEORGE BALFOUR, MD
ORTHOPEDIC SECTION, PSJMC
MODERATOR: Stephan Yacoubian, MD; Chairman, Orthopedic Section, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Drs. Raven and Balfour state they have no disclosures. Dr. Yacoubian states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - perform an initial history, evaluation, examination, and work-up of the patient presenting with hand pain and make the differential diagnosis.
- appropriately order diagnostic imaging.
- appropriately manage hand pain and know when to refer to a specialist.
- determine cultural factors that can affect the epidemiology or perception of hand injuries
Satisfies DHS radiology requirement. This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Current Trends in Spine Management
YURI FALKINSTEIN, MD
RICHARD FELDMAN, MD
ORTHOPEDIC SECTION, PSJMC
MODERATOR: Stephan Yacoubian, MD; Chairman, Orthopedic Section, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Drs. Falkinstein and Feldman state they have no disclosures. Dr. Yacoubian states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - perform an initial history, evaluation, examination, and work-up of the patient presenting with low back pain and make the differential diagnosis.
- appropriately order diagnostic imaging.
- appropriately manage acute and chronic low back pain and know when to refer to a specialist.
- determine cultural factors that can affect the epidemiology or perception of low back pain.
Satisfies DHS radiology requirement. This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Sports Medicine: Shoulder Update, 2010 & Total Joint Replacement 2010 Update
STEPHAN YACOUBIAN, MD
CHAIRMAN, ORTHOPEDIC SECTION, PSJMC SHAHAN YACOUBIAN, MD
ORTHOPEDIC SECTION, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Drs. Stephan and Shahan Yacoubian state they have no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - recognize the signs and symptoms of shoulder and joint injuries.
- determine appropriate work-up and/or referral.
incorporate current evidence-based strategies for successful surgery and management of shoulder and joint injuries.- identify cultural/linguistic factors or cultural disparities that impact the long-term outcomes of patients with orthopedic injuries.
Satisfies DHS radiology requirement. This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Surgical and Medical-Legal Implications of Ruptured Intracranial Aneurysms
STEVEN GIANNOTTA, M.D.
DEPARTMENT OF SURGERY, PSJMC
PROFESSOR AND CHAIRMAN, DEPT. OF NEUROLOGICAL SURGERY
KECK SCHOOL OF MEDICINE, USC
MODERATOR: Nouzhan Sehati, M.D.; Department of Surgery, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Giannotta states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - recognize the risk factors for and clinical manifestations of ruptured intracranial aneurysms.
- conduct an appropriate work-up and make the diagnosis.
- choose appropriate intervention for ruptured intracranial aneurysm repair.
- identify cultural factors or cultural disparities that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of ruptured intracranial aneurysms.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
The Diagnosis and Managment of Sports-Related Concussion: 2010 Update
ANDREW BLECHER, M.D.
DIR., CENTER FOR REHAB MEDICINE, SOUTHERN CALFORNIA ORTHOPEDIC INSTITUTE
MODERATOR: Sheldon Kishineff, MD; Pediatric Liaison, Medical Education Committee, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Blecher states he has no disclosures. Dr. Kishineff states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - determine the signs and symptoms and most likely scenario leading to concussion in the athlete.
- determine the appropriate work-up for the diagnosis of concussion in the athlete.
appropriately manage concussion in the athlete, and implement a plan for assessment, diagnosis and long-term follow-up of post concussive symptoms.- identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of concussion in the athlete.
Satisfies DHS radiology requirement. This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Disney Cancer Center
RAUL MENA, MD
MEDICAL DIRECTOR, CANCER PROGRAM, PSJMC
MODERATOR: Barry Wolfman, CEO, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Mena states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - Enjoy peace and tranquility in the world.
- Improved understanding and access to the Roy and Patricia Disney Family Cancer Center.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Targeted Radiation Therapy for Early State Lung Cancer
MONA SANGHANI, M.D.
DEPT. OF RADIATION ONCOLOGY, PSJMC
MODERATOR: Rex Hoffman, Chairman, Cancer Committee, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Saghani states she has no disclosures. Dr. Hoffman states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: -
determine indications and patient selection for radiotherapy in lung cancer patients.
- describe efficacy, safety and long-term outcomes for radiotherapy in lung cancer patients.
- identifycultural/linguistic factors that impact the treatment, clinical course, and/or long-term outcomes of radiotherapy in lung cancer patients.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM
|
|
Play Video
|
|
|
|
Fertility Preservation in Cancer Patients: There's Life After Cancer
TINA KOOPERSMITH, M.D.
DEPARTMENT OF GYN, PSJMC
MODERATOR: RICHARD FRIEDMAN, MD; DEPARTMENT OF GYN/ONCOLOGY, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Koopersmith states she has no disclosures. Dr. Friedman states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to:
- discuss why fertility preservation options are important for young women with cancer.
- determine efficacy and safety of current techniques for fertility preservation.
- determine efficacy and safety of current techniques for invitro fertilization.
- avoid medical risks associated with induction of ovulation, pregnancy, and cancer.
- identifycultural/linguistic factors, cultural disparities, and/or moral and ethical dilemmas that impact fertility preservation in women with cancer.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM
|
|
Play Video
|
|
|
|
Current Concepts and Strategies in Pain Management
RAYMOND TATEVOSSIAN, M.D.
CHAIRMAN, PAIN & PALLIATIVE CARE COMMITTEE, PSJMC
MODERATOR: Rex Hoffman, Chairman, Cancer Committee, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Tatevossian states he has no disclosures. Dr. Hoffman states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to:
- recognize the symptoms and mechanism of common pain syndromes and make an accurate diagnosis.
- implement safe and effective strategies to treat common pain syndromes.
- identify cultural/linguistic factors that impact pain expression and pain management.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM
|
|
Play Video
|
|
|
|
POLST: What Does it Mean? Who is it For?
ISAAC VIELMA, M.D.
MEDICAL DIRECTOR, PALLIATIVE CARE, PSJMC
MODERATOR: JACQUELINE STELTZ-LENARKSY; MANAGER, CONTINUING MEDICAL EDUCATION DEPARTMENT, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Vielma states he has no disclosures. Ms. Steltz-Learnsky states she has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to: - define POLST, determine to whom it applies, summarize the law and the POLST form.
- articulate the legal and ethical rationale for POLST.
- outline recommended policies and implement POLST.
- identify cultural/linguistic factors that impact the implementation and intended outcomes of POLST.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM
|
|
Play Video
|
|
|
|
The Cutting Edge: Caring for Adult Survivors of Childhood Cancer at PSJMC
DAVID FREYER, DO
DIR., LIFE SURVIVORSHIP AND TRANSITION PROGRAM, CHILDRENS HOSPITAL LOS ANGELES
MODERATOR: LISA SCHWARTZ, M.D., MEDICAL DIRECTOR, INTEGRATIVE MEDICINE, DFCC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Freyer states he has no disclosures. Dr. Schwartz states she has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to:
- discuss the need for physicians and mental health professionals trained in the long-term follow-up of childhood cancer survivors, as it relates to toxicity of surgery, chemotherapy and radiation treatment, and post-traumatic stress.
- discuss the lack of progress in survival rates for young adults with cancer.
- incorporate best practices in the follow-up care of adult survivors of childhood cancer.
- identify cultural/linguistic factors that impact the long-term care of adult survivors of childhood cancer.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM
|
|
Play Video
|
|
|
|
New Advances in Radiation Oncology for Gastrointestinal Malignancies
LAUREN VANDERSPEK, M.D.
DEPARTMENT OF RADIATION ONCOLOGY PSJMC
MODERATOR: MARC BOTNICK, M.D.; DEPARTMENT OF RADIATION ONCOLOGY, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. VanderSpek states she has no disclosures. Dr. Botnick states he has no disclosures.
OBJECTIVES
At the end of the presentation, attendees will be able to:
- determine indications and patient selection for radiotherapy in GI cancer patients.
- describe efficacy, safety and long-term outcomes for radiotherapy in GI cancer patients.
- identify cultural/linguistic factors that impact the treatment, clinical course, and/or long-term outcomes of radiotherapy in GI cancer patients.
Satisfies DHS radiology requirement. This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
The Importance of Clinical Trials in a Community Practice/Hospital
PETER J. ROSEN, M.D.
MEDICAL DIRECTOR, TOWER CANCER RESEARCH FOUNDATION
MODERATOR:Rex Hoffman, M.D.; Chairman, Cancer Commitee, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following:
Dr. Rosen states is on the Speakers Bureau for Genentech, Allos, Spectrum, Amgen, Sandoz, and Cephacon and on the Advisory Board for Sandoz and Cephacon. Dr. Hoffman states he has no disclosures. It is our policy to review presentations ahead of time in order to indentify adn resolves any potential conflicts. No conflicts were indentified in the review of this presentation.
Objectives
At the end of the presentation, attendees will be able to: - define the basics of a clinical trial, including Phases1-4
- determin who is a candidate for a clinical trial
- describe thte rationale for clinical trials, including quality improvement
- discuss the ethical basis of placebos.
- identify cultural disparities in the licnical trial process that impact patient selections for and/or outcomes of clinical trials
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM.
|
|
Play Video
|
|
|
|
Surviving Sepsis Campaign
ASHRAF KHAN, M.D.
DEPARTMENT OF MEDICINE, PSJMC
MODERATOR: DANIEL DEA, MD; DEPARTMENT OF MEDICINE, PSJMC
FACULTY DISCLOSURE: According to CMA guidelines for faculty/planner disclosure of commercial support, we are required to announce the following: Dr. Khan states he has no disclosures.
OBJECTIVES At the end of the presentation, attendees will be able to:
- define and distinguish sepsis, severe sepsis and septic shock.
- recognize patients who are at risk for developing sepsis
- order appropriate tests for sepsis
- treat according to evidence-based guidelines, and/or know when to call the Rapid Response Team
- identify cultural/linguistic factors that impact the epidemiology, incidence, diagnosis, treatment, clinical course, and/or long-term outcomes of sepsis.
This activity is designated for a maximum of .75 AMA PRA Category 1 Credit(s)TM
|
|
Play Video
|
|
|
|
|
|